CSIMarket
 
Galmed Pharmaceuticals Ltd   (GLMD)
Other Ticker:  
 
 
Price: $0.3107 $0.01 1.835%
Day's High: $0.35 Week Perf: -13.69 %
Day's Low: $ 0.30 30 Day Perf: -18.26 %
Volume (M): 302 52 Wk High: $ 5.63
Volume (M$): $ 94 52 Wk Avg: $1.05
Open: $0.30 52 Wk Low: $0.26



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 18
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd is a pharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of liver diseases. The company is based in Israel and operates globally.

Galmed is primarily known for its lead product candidate, Aramchol, which is under investigation for the treatment of non-alcoholic steatohepatitis (NASH), a progressive form of fatty liver disease. Aramchol has shown promising results in clinical trials and has the potential to address the large unmet medical need in the NASH market.

In addition to Aramchol, Galmed is also engaged in the development of other drug candidates targeting liver diseases, including fibrosis and primary sclerosing cholangitis. The company's pipeline is focused on addressing various stages and aspects of liver disease progression.

Galmed has strategic partnerships and collaborations with other pharmaceutical companies to explore the potential of its drug candidates in combination therapies and to expand its global reach. The company has a strong commitment to research and development, aiming to bring innovative therapies to patients with liver diseases.


   Company Address: 16 Tiomkin Street Tel Aviv 6578317
   Company Phone Number: 693.8448   Stock Exchange / Ticker: NASDAQ GLMD
   GLMD is expected to report next financial results on March 28, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Neurogene Inc. Breaks Ground in Rare Neurological Disorder Research with Expansion of NGN-401 Trial

Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment.
Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.

Eyenovia Inc

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain



Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future.
1. Co-Promotion Agreement with NovaBay Pharmaceuticals:
Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition.
Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com